WAS
RPRX icon

Winch Advisory Services’s Royalty Pharma RPRX Stock Holding History

Winch Advisory Services’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-300
Closed -$7.65K – 534
2024
Q4 		$7.65K Buy
+300
New +$7.96K ﹤0.01% 325

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Winch Advisory Services's RPRX Position: Q1 2025 in Review

Winch Advisory Services sold out of Royalty Pharma (RPRX) in Q1 2025, closing a stake of 300 shares — an estimated $7.65K sold.

Winch Advisory Services first reported a position in RPRX in Q4 2024 and held it in 1 quarter. The position peaked at $7.65K in Q4 2024. 447 funds tracked by Wall St. Rank hold RPRX as of Q1 2025.

  • Winch Advisory Services reported no remaining Royalty Pharma position as of Q1 2025 after selling out during the quarter.
  • Winch Advisory Services sold 300 Royalty Pharma shares in Q1 2025, an estimated $7.65K.
  • Winch Advisory Services first reported a position in Royalty Pharma in Q4 2024 and held it in 1 quarter.
  • Winch Advisory Services's Royalty Pharma position peaked at $7.65K in Q4 2024.
  • 447 funds tracked by Wall St. Rank held Royalty Pharma as of Q1 2025.

Based on Winch Advisory Services's 13F filing for Q1 2025, filed 6 May 2025.